Identification of novel brain biomarkers

Clinical Chemistry

Volumn 52, Issue 9, 2006, Pages 1713-1721

  Laterza, Omar F ^a,b   Modur, Vijay R ^a   Crimmins, Dan L ^a   Olander, Jitka V ^a   Landt, Yvonne ^a   Lee, Jin Moo ^a   Ladenson, Jack H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; DNA; GENE PRODUCT; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE DECARBOXYLASE 67; MESSENGER RNA; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; NEURONATIN; NEUROSERPIN; NUCLEOTIDE; OLFACTOMEDIN; PROTEIN; PROTEIN S100B; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG; VISININ LIKE PROTEIN 1; ZYGIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CEREBROSPINAL FLUID; CONTROLLED STUDY; DNA SEQUENCE; EXPRESSED SEQUENCE TAG; GENE; GENE EXPRESSION; HUMAN; IMMUNOASSAY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN SYNTHESIS; RAT; SPECTROPHOTOMETRY; TISSUE MICROARRAY; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOASSAY; MICE; MICE, INBRED C57BL; NEUROCALCIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SPECIFICITY; RATS; RATS, SPRAGUE-DAWLEY; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS;

EID: 33748300597     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.070912     Document Type: Article

References (38)

1. Schwamm LH, Pancioli A, Acker JE III, Goldstein LB, Zorowitz RD, Shepard TJ, et al. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Circulation 2005;111:1078-91.
2. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet 2003;362:1211-24.
3. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am College Cardiol 2000;36:959-69.
4. Rothermundt M, Peters M, Prehn, JHM, Arolt V. S100B in brain damage and neurodegeneration. Microsc. Res. Tech. 2003;60:614-32.
5. Foerch C, Otto B, Singer OC, Neumann-Haefelin T, Yan B, Berkefeld J, et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004;35:2160-4.
6. Vaage J, Anderson R. Biochemical markers of neurologic injury in cardiac surgery: the rise and fall of S100β. J Thorac Cardiovasc Surg 2001;122:853-5.
7. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. Neurosurgery 2001;48:1255-60.
8. Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J. Increase in Serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources. Ann Thorac Surg 2001;71:1512-7.
9. Schmechel D, Marangos PJ, Zis AP, Brightman M, Goodwin FK. Brain enolases as specific markers of neuronal and glial cells. Science 1978;199:313-5.
10. Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18:911-8.
11. Anand N, Stead LG. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc Dis 2005;20:213-9.
12. Muley T, Ebert W, Stieber P, Raith H, Holdenrieder S, Nagel D, et al. Technical performance and diagnostic utility of the new Elecsys® neuron-specific enolase enzyme immunoassay. Clin Chem Lab Med 2003;41:95-103.
13. Beaudeux J, Léger P, Dequen L, Gandjbakhch I, Coriat P, Foglietti M. Influence of hemolysis on the measurement of S-100β protein and neuron-specific enolase plasma concentrations during coronary artery bypass grafting. Clin Chem 2000;46:989-90.
14. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJB. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000;31:2670-7.
15. Pelsers MM, Glatz JFC. Detection of brain injury by fatty acid-binding proteins. Clin Chem Lab Med 2005;43:802-9.
16. Fon EA, Mackey A, Cote R, Wolfson C, McIlraith DM, Leclerc J, et al. Hemostatic markers in acute transient ischemic attacks. Stroke 1994;25:282-6.
17. Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic markers in acute ischemic stroke: association with stroke type, severity, and outcome. Stroke 1996;27:1296-1300.
18. Castillo J, Rodriguez I. Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004;17(Suppl 1):7-18.
19. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001;32:1759-66.
20. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34:40-6.
21. McGirt MJ, Lynch JR, Blessing R, Warner DS, Friedman AH, et al. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2002;51:1128-35.
22. Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, et al. Early biomarkers of sroke. Clin Chem 2003;49:1733-9.
23. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke 2004;35:57-63.
24. Lubec G, Krapfenbauer K, Fountoulakis M. Proteomics in brain research: potentials and limitations. Prog Neurobiol 2003;69:193-211.
25. Gauss C, Kalkum M, Lowe M, Lehrach H, Klose J. Analysis of the mouse proteome. (I) Brain proteins: separation by two-dimensional electrophoresis and identification by mass spectrometry and genetic variation. Electrophoresis 1999;20:575-600.
26. Lescuyer P, Allard L, Zimmermann-Ivol CG, Burgess JA, Hughes-Frutiger S, Burkhard PR, et al. Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics 2004;4:2234-41.
27. Prados J, Kalousis A, Sanchez JC, Allard L, Carrette O, Hilario M. Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents. Proteomics 2004;4:2320-32.
28. Chomczynski P, Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
29. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-80.
30. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nat Genet 1999;21(Suppl 1):20-4.
31. Li A, Crimmins DL, Luo Q, Hartupee J, Landt Y, Ladenson JH, et al. Expression of a novel regenerating gene product, Reg IV, by high density fermentation in Pichia pastoris: production, purification, and characterization. Protein Expr Purif 2003;31:197-206.
32. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998;392:408-11.
33. Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
34. Paterlini M, Revilla V, Grant AL, Wisden W. Expression of the neuronal calcium sensor protein family in the rat brain. Neuroscience 2000;99:205-16.
35. Cornford EM, Hyman S. Blood-brain barrier permeability to small and large molecules. Adv Drug Deliv Rev 1999;36:145-63.
36. Hampel H, Kötter HU, Möller HJ. Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Alzheimer Dis Assoc Disord 1997;11:78-87.
37. Gingrich MB, Traynelis SF. Serine proteases and brain damage - is there a link? Trends Neurosci 2000;23:399-407.
38. Rosengren HC, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2000;2:199-206.